Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > LATAM Growth ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by porksnifferon Sep 14, 2020 10:49pm
91 Views
Post# 31558078

RE:LATAM Growth ...

RE:LATAM Growth ...
drippingsnot wrote: As we said previously, Moksha8 has been on fire - signing up two more drugs on 9/11.

See the attached article link if you are interested. 

https://www.pharmiweb.com/press-release/2020-09-11/luye-pharma-signs-two-agreements-in-latin-america-global-business-system-for-seroquel-continues-to



On fire?? looollllll

MugSnots, I notice you are no longer pumping ONTX. Why is that. Chief?

It is because it's 20 cents and going down? What about Synergy? Is it below 5 cents yet? lol
How much was invested there? 

Can you remind the board how much was invested in these turds and at what price?

Can you also tell the board what our losses on these are?

Can you also tell us how much YOU have personally lost with ONTX?

Thanks, lots of questions but you always have all the answers will be looking for your musings. lol
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities